Prime Medicine Stock (NASDAQ:PRME)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$4.03

52W Range

$3.28 - $9.86

50D Avg

$3.90

200D Avg

$5.68

Market Cap

$475.32M

Avg Vol (3M)

$1.42M

Beta

2.18

Div Yield

-

PRME Company Profile


Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

234

IPO Date

Oct 20, 2022

Website

PRME Performance


PRME Financial Summary


Dec 23Dec 22Dec 21
Revenue-$5.21M-
Operating Income$-204.79M$-116.54M$-84.47M
Net Income$-198.13M$-121.82M$-165.37M
EBITDA$-204.79M$-108.42M$-83.52M
Basic EPS$-2.18$-3.59$-2.30
Diluted EPS$-2.18$-3.59$-2.30

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
SANASana Biotechnology, Inc.
DNAGinkgo Bioworks Holdings, Inc.
CRSPCRISPR Therapeutics AG
BPMCBlueprint Medicines Corporation
RPHMReneo Pharmaceuticals, Inc.
IPSCCentury Therapeutics, Inc.
NTLAIntellia Therapeutics, Inc.
EDITEditas Medicine, Inc.
VERVVerve Therapeutics, Inc.
RLAYRelay Therapeutics, Inc.
CRBUCaribou Biosciences, Inc.
RPRXRoyalty Pharma plc
OCEAOcean Biomedical, Inc.
BEAMBeam Therapeutics Inc.
LIFEaTyr Pharma, Inc.